FR16C0028I1 - VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - Google Patents

VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS

Info

Publication number
FR16C0028I1
FR16C0028I1 FR16C0028C FR16C0028I1 FR 16C0028 I1 FR16C0028 I1 FR 16C0028I1 FR 16C0028 C FR16C0028 C FR 16C0028C FR 16C0028 I1 FR16C0028 I1 FR 16C0028I1
Authority
FR
France
Prior art keywords
viral vectors
therapeutic methods
vectors
methods
treat disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Georgetown University
Catherex Inc
Original Assignee
General Hospital Corp
Georgetown University
Catherex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23067509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0028(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Georgetown University, Catherex Inc filed Critical General Hospital Corp
Publication of FR16C0028I1 publication Critical patent/FR16C0028I1/en
Application granted granted Critical
Publication of FR16C0028I2 publication Critical patent/FR16C0028I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
FR16C0028C 2001-03-27 2016-06-15 VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS Active FR16C0028I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27906901P 2001-03-27 2001-03-27
PCT/US2002/009512 WO2002076216A1 (en) 2001-03-27 2002-03-27 Viral vectors and their use in therapeutic methods

Publications (2)

Publication Number Publication Date
FR16C0028I1 true FR16C0028I1 (en) 2016-07-22
FR16C0028I2 FR16C0028I2 (en) 2018-05-11

Family

ID=23067509

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0028C Active FR16C0028I2 (en) 2001-03-27 2016-06-15 VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS

Country Status (9)

Country Link
US (6) US7749745B2 (en)
EP (1) EP1381280B1 (en)
JP (2) JP4212897B2 (en)
AT (1) ATE508635T1 (en)
AU (1) AU2002306919B2 (en)
CA (1) CA2441663C (en)
ES (1) ES2366608T3 (en)
FR (1) FR16C0028I2 (en)
WO (1) WO2002076216A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
AU2002306919B2 (en) * 2001-03-27 2007-11-22 Tomoki Todo Viral vectors and their use in therapeutic methods
JP2005519091A (en) * 2002-03-01 2005-06-30 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Prevention of cancer recurrence and metastasis
ES2463442T3 (en) 2004-03-31 2014-05-28 Tomoki Todo Enhancer of anti-cancer activity in viral therapy and method of prevention or treatment of cancer
AU2005235826A1 (en) * 2004-03-31 2005-11-03 Tomoki Todo Method of constructing recombinant herpes simplex virus
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
US9267151B2 (en) * 2008-08-20 2016-02-23 Brainco Biopharma, S.L. STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
WO2011101912A1 (en) 2010-02-19 2011-08-25 国立大学法人東京大学 Recombinant herpes virus and pharmaceutical composition containing recombinant herpes virus
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PL2753355T3 (en) 2011-09-08 2019-04-30 Benevir Biopharm Inc Oncolytic herpes simplex virus and therapeutic uses thereof
ES2781852T3 (en) 2013-10-28 2020-09-08 Univ Pittsburgh Commonwealth Sys Higher Education Oncolytic HSV vector
MA39818A (en) 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
WO2016100364A1 (en) 2014-12-18 2016-06-23 Amgen Inc. Stable frozen herpes simplex virus formulation
EP3307330B1 (en) 2015-06-15 2021-03-10 New York University Method of treatment using oncolytic viruses
EP3778881A1 (en) 2016-01-08 2021-02-17 Replimune Limited Modified oncolytic virus
RU2021114137A (en) 2016-01-27 2021-05-25 Онкорус, Инк. ONCOLYTIC VIRAL VECTORS AND THEIR APPLICATION
WO2017223146A1 (en) 2016-06-22 2017-12-28 Aeras Recombinant cytomegalovirus vectors as vaccines for tuberculosis
RU2021127872A (en) 2016-06-30 2021-11-09 Онкорус, Инк. DELIVERY OF THERAPEUTIC POLYPEPTIDES THROUGH PSEUDOTYPED ONCOLYTIC VIRUSES
WO2018170133A1 (en) 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN106974942A (en) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 Application of the recombination oncolytic II herpes simplex virus types in anti-lymphadenoma, cancer of the esophagus, breast cancer, pancreatic cancer drug is prepared
JP7249323B2 (en) 2017-07-26 2023-03-30 オンコラス， インコーポレイテッド Oncolytic virus vector and use thereof
UY37829A (en) 2017-08-03 2019-01-31 Amgen Inc INTERLEUCINE MUTEINS 21 AND TREATMENT METHODS
MA49849A (en) 2017-08-07 2020-06-17 Amgen Inc TREATMENT OF NEGATIVE TRIPLE BREAST CANCER OR COLORECTAL CANCER CONTAINING HEPATIC METASTASIS WITH ANTI-PD-L1 ANTIBODY AND ONCOLYTIC VIRUS
IL293443A (en) 2017-09-08 2022-07-01 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3697806A4 (en) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberculosis antigen cassettes
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
PE20211270A1 (en) 2018-01-12 2021-07-19 Amgen Inc ANTI-PD-1 ANTIBODIES AND TREATMENT METHODS
CA3095427A1 (en) 2018-03-30 2019-10-03 Tomoki Todo Swelling-suppressive oncolytic virus
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
JP2022516077A (en) 2018-12-27 2022-02-24 アムジェン インコーポレイテッド Freeze-dried virus preparation
KR20210135532A (en) 2019-03-05 2021-11-15 암젠 인크 Use of oncolytic viruses for the treatment of cancer
TW202102543A (en) 2019-03-29 2021-01-16 美商安進公司 Use of oncolytic viruses in the neoadjuvant therapy of cancer
US20230147832A1 (en) * 2020-01-22 2023-05-11 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
WO2024038857A1 (en) * 2022-08-16 2024-02-22 具紀 藤堂 Pharmaceutical composition containing herpes simplex virus vector

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659628B1 (en) * 1990-03-16 1992-09-18 Marin S Communication BOX OR CASE DEVICE WITH MOBILE COVER.
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5750398A (en) 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US6261552B1 (en) * 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
KR100802403B1 (en) 2000-01-21 2008-02-13 바이오벡스 리미티드 Virus Strains
AU6814601A (en) * 2000-06-01 2001-12-11 Sloan Kettering Inst Cancer Use of mutant herpes viruses and anticancer agents in the treatment of cancer
AU2002306919B2 (en) * 2001-03-27 2007-11-22 Tomoki Todo Viral vectors and their use in therapeutic methods

Also Published As

Publication number Publication date
EP1381280A4 (en) 2006-06-14
JP4212897B2 (en) 2009-01-21
WO2002076216A1 (en) 2002-10-03
US20200345835A1 (en) 2020-11-05
US20110070262A1 (en) 2011-03-24
AU2002306919B2 (en) 2007-11-22
ATE508635T1 (en) 2011-05-15
US20150071965A1 (en) 2015-03-12
ES2366608T3 (en) 2011-10-21
CA2441663C (en) 2013-01-22
US10532095B2 (en) 2020-01-14
EP1381280A1 (en) 2004-01-21
US8470577B2 (en) 2013-06-25
US9555072B2 (en) 2017-01-31
JP2009060907A (en) 2009-03-26
US20130280299A1 (en) 2013-10-24
US8871193B2 (en) 2014-10-28
US20020187163A1 (en) 2002-12-12
US20170290908A1 (en) 2017-10-12
EP1381280B1 (en) 2011-05-11
FR16C0028I2 (en) 2018-05-11
US7749745B2 (en) 2010-07-06
JP2004528836A (en) 2004-09-24
CA2441663A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
FR16C0028I2 (en) VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
DK1556021T3 (en) Pharmaceutical compositions comprising flavonoids and menthol as well as methods of treatment using said compositions
NO20050795L (en) Compounds, compositions and methods for utilizing the same
NO20053817D0 (en) Preparations and Methods for Antiviral Combination Therapy.
DK1368060T3 (en) HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease
NO20041917L (en) Specific agents that bind human angiopoietin-2
BR0309665A (en) Treatment of alpha-galactosidase deficiency at
BRPI0411900A (en) antiviral compounds and methods
ATE433973T1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
ATE376832T1 (en) DELAYED RELEASE FORMULATIONS OF OXYMORPHONE
DE60137337D1 (en) PREVENTIVE AND THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST VACCINIAVIRUSANTIGENE
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
HUP0303917A2 (en) Combinations of sterol absorption inhibitir(s) with blood modifier(s) and their use for treating vascular conditions
CY1107531T1 (en) USE OF PROTECTION ANALYTES FOR THE TREATMENT OF DRY EYE DISORDERS
DK1097173T3 (en) Use of IL-2 peptides and derivatives thereof as therapeutic agents
MXPA04006572A (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections.
DK1381382T3 (en) Methods and Preparations for the Treatment of Eye Diseases
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
DE602005016552D1 (en) PARAPOCK VIRUS IN COMBINATION WITH OTHER ANTIVIRAL AGENTS FOR THE TREATMENT OF HIV / AIDS
TR200200278T2 (en) Calcilitic compositions
NO20051301L (en) Proteintyrosinforfataseinhibitorer
DE602004019541D1 (en) CYCLOALKYLÄBÜ CONDENSED INDOLE
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE
DK1461042T3 (en) Use of desoxypeganine in the treatment of clinical depression
NO20005548L (en) Mykobakterieinhibitorer